Orexo AB
STO:ORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dareway Software Co Ltd
SSE:688579
|
CN |
|
Highcroft Investments PLC
LSE:HCFT
|
UK |
|
Kian Shen Corp
TWSE:1525
|
TW |
|
I
|
IFGL Refractories Ltd
NSE:IFGLEXPOR
|
IN |
|
X
|
XiAn Bright Laser Technologies Co Ltd
SSE:688333
|
CN |
|
S
|
SYF Resources Bhd
KLSE:SYF
|
MY |
|
C
|
Crown Castle Inc
SWB:8CW
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
|
Orexo AB
STO:ORX
|
774.6m SEK |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD |
Loading...
|
Market Distribution
| Min | -855 316.7% |
| 30th Percentile | 30.8% |
| Median | 44.8% |
| 70th Percentile | 66% |
| Max | 113 764.6% |
Other Profitability Ratios
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Orexo AB is 44.2%, which is below its 3-year median of 79%.
Over the last 3 years, Orexo AB’s Gross Margin has decreased from 83.6% to 44.2%. During this period, it reached a low of 44.2% on Jan 1, 2026 and a high of 89.2% on Sep 30, 2025.
